Switch theme
Sign up to access all valuation multiples
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
2007
61
LTM Revenue $6.4M
Last FY EBITDA -$73.0M
-$7.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioAtla has a last 12-month revenue (LTM) of $6.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BioAtla achieved revenue of $11.0M and an EBITDA of -$73.0M.
BioAtla expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioAtla valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.4M | XXX | $11.0M | XXX | XXX | XXX |
| Gross Profit | $6.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$73.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -664% | XXX | XXX | XXX |
| EBIT | -$71.2M | XXX | -$73.9M | XXX | XXX | XXX |
| EBIT Margin | -1104% | XXX | -672% | XXX | XXX | XXX |
| Net Profit | -$68.1M | XXX | -$69.8M | XXX | XXX | XXX |
| Net Margin | -1055% | XXX | -634% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BioAtla's stock price is $0.
BioAtla has current market cap of $23.9M, and EV of -$7.9M.
See BioAtla trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$7.9M | $23.9M | XXX | XXX | XXX | XXX | $-1.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BioAtla has market cap of $23.9M and EV of -$7.9M.
BioAtla's trades at -0.7x EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate BioAtla's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioAtla has a P/E ratio of -0.4x.
See valuation multiples for BioAtla and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $23.9M | XXX | $23.9M | XXX | XXX | XXX |
| EV (current) | -$7.9M | XXX | -$7.9M | XXX | XXX | XXX |
| EV/Revenue | -1.2x | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -1.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioAtla's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.4M for the same period.
BioAtla's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioAtla's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioAtla and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -664% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 574% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 772% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioAtla acquired XXX companies to date.
Last acquisition by BioAtla was XXXXXXXX, XXXXX XXXXX XXXXXX . BioAtla acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioAtla founded? | BioAtla was founded in 2007. |
| Where is BioAtla headquartered? | BioAtla is headquartered in United States of America. |
| How many employees does BioAtla have? | As of today, BioAtla has 61 employees. |
| Who is the CEO of BioAtla? | BioAtla's CEO is Dr. Jay M. Short,PhD. |
| Is BioAtla publicy listed? | Yes, BioAtla is a public company listed on NAS. |
| What is the stock symbol of BioAtla? | BioAtla trades under BCAB ticker. |
| When did BioAtla go public? | BioAtla went public in 2020. |
| Who are competitors of BioAtla? | Similar companies to BioAtla include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BioAtla? | BioAtla's current market cap is $23.9M |
| What is the current revenue of BioAtla? | BioAtla's last 12 months revenue is $6.4M. |
| What is the current EV/Revenue multiple of BioAtla? | Current revenue multiple of BioAtla is -1.2x. |
| Is BioAtla profitable? | Yes, BioAtla is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
